Literature DB >> 15312867

Potential role of humoral immunity in cardiac dysfunction of patients suffering from dilated cardiomyopathy.

Alexander Staudt1, Yvonne Staudt, Marcus Dörr, Marco Böhm, Fabian Knebel, Astrid Hummel, Lydia Wunderle, Malte Tiburcy, Klaus D Wernecke, Gert Baumann, Stephan B Felix.   

Abstract

OBJECTIVES: This research was conducted to evaluate the role played by the humoral immune system in cardiac dysfunction among dilated cardiomyopathy (DCM) patients, as enabled by immunoadsorption therapy (IA) that effectively removes functionally active cardiac autoantibodies from plasma.
BACKGROUND: Various circulating autoantibodies have been detected among patients suffering from DCM.
METHODS: Before IA, antibodies were purified from plasma of 45 DCM patients (left ventricular ejection fraction [LVEF] <30%). We analyzed the functional effects of antibodies (300 mg/l) on calcium transients and on systolic cell shortening in adult rat cardiomyocytes. After this in vitro analysis, IA was performed in four courses at one-month intervals until month 3.
RESULTS: Antibodies from 29 patients induced a reduction (>10%) in calcium transients (mean reduction: -16.5 +/- 1.9%) and a simultaneous reduction (>10%) of cell shortening (mean reduction: -21.2 +/- 1.8%) on cardiomyocytes (p < 0.001) (cardiodepressant group). Antibodies from 16 patients did not significantly influence calcium transients and cell shortening (<10%) (non-cardiodepressant group). During the first IA course, the cardiodepressant group demonstrated an acute increase in cardiac index (CI) from 2.2 +/- 0.1 l/min/m(2) to 2.9 +/- 0.1 l/min/m(2) (p < 0.001). In the non-cardiodepressant group, hemodynamics did not significantly change throughout three months. After three months before the final IA course (prolonged effects), the CI was 2.1 +/- 0.1 l/min/m(2) in the non-cardiodepressant group and 2.9 +/- 0.1 l/min/m(2) in the cardiodepressant group (p < 0.001). After three months LVEF increased only in the cardiodepressant group: from 20.8 +/- 1% to 30.5 +/- 1% (p < 0.01).
CONCLUSIONS: In the majority of DCM patients, disturbances of humoral immunity with production of cardiodepressant antibodies may play a functional role in cardiac dysfunction. Evidence of cardiodepressant antibodies predicts hemodynamic benefits during IA.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15312867     DOI: 10.1016/j.jacc.2004.04.055

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  24 in total

1.  B-cell epitope spreading is a critical step for the switch from C-protein-induced myocarditis to dilated cardiomyopathy.

Authors:  Yoh Matsumoto; Il-Kwon Park; Kuniko Kohyama
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

Review 2.  Immune modulation in heart failure: past challenges and future hopes.

Authors:  Jose H Flores-Arredondo; Gerardo García-Rivas; Guillermo Torre-Amione
Journal:  Curr Heart Fail Rep       Date:  2011-03

Review 3.  Autoantibodies and cardiovascular dysfunction: cause or consequence?

Authors:  Yuji Nagatomo; W H Wilson Tang
Journal:  Curr Heart Fail Rep       Date:  2014-12

Review 4.  Inflammation, ECG changes and pericardial effusion: whom to biopsy in suspected myocarditis?

Authors:  M Pauschinger; M Noutsias; D Lassner; H-P Schultheiss; U Kuehl
Journal:  Clin Res Cardiol       Date:  2006-08-16       Impact factor: 5.460

Review 5.  [Immunoadsorption for treatment of dilated cardiomyopathy].

Authors:  S B Felix; M Dörr; L R Herda; D Beug; A Staudt
Journal:  Internist (Berl)       Date:  2008-01       Impact factor: 0.743

6.  Immunoadsorption and subsequent immunoglobulin substitution decreases myocardial gene expression of desmin in dilated cardiomyopathy.

Authors:  Angela Kallwellis-Opara; Alexander Staudt; Christiane Trimpert; Michel Noutsias; Uwe Kühl; Matthias Pauschinger; Heinz-Peter Schultheiss; Markus Grube; Michael Böhm; Gert Baumann; Uwe Völker; Heyo K Kroemer; Stephan B Felix
Journal:  J Mol Med (Berl)       Date:  2007-10-09       Impact factor: 4.599

7.  Outcomes of plasma exchange for severe dilated cardiomyopathy in children.

Authors:  Keiichi Koizumi; Minako Hoshiai; Takako Toda; Nobuyuki Katsumata; Hiroaki Kise; Yohei Hasebe; Yousuke Kouno; Shigeaki Kaga; Shoji Suzuki; Kanji Sugita
Journal:  Heart Vessels       Date:  2016-04-27       Impact factor: 2.037

Review 8.  Pathological ventricular remodeling: mechanisms: part 1 of 2.

Authors:  Jana S Burchfield; Min Xie; Joseph A Hill
Journal:  Circulation       Date:  2013-07-23       Impact factor: 29.690

9.  Autoantibodies Specifically Against β1 Adrenergic Receptors and Adverse Clinical Outcome in Patients With Chronic Systolic Heart Failure in the β-Blocker Era: The Importance of Immunoglobulin G3 Subclass.

Authors:  Yuji Nagatomo; Daniel Li; Jennifer Kirsop; Alan Borowski; Akanksha Thakur; W H Wilson Tang
Journal:  J Card Fail       Date:  2016-03-17       Impact factor: 5.712

10.  Plasma exchange for removal of antibeta1-adrenergic receptor antibody in a small child with dilated cardiomyopathy.

Authors:  Hisashi Sugiyama; Minako Hoshiai; Kanji Sugita; Ken-ichi Matsuda
Journal:  Pediatr Cardiol       Date:  2008-11-22       Impact factor: 1.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.